Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 20 for “"KRASG12C"”.

  1. Interrogating therapeutic resistance to oncogenic KRASG12C-based therapies in colorectal cancer

    … of novel covalent inhibitors selective for KRASG12C mutation have entered the clinic, which has not only marked a major milestone in cancer drug discovery but has also intensified efforts to directly target other KRAS mutations that have also successfully entered the clinic. However, …

    uthsc Repository record for Interrogating therapeutic resistance to oncogenic KRASG12C-based therapies in colorectal cancer (opens in a new tab)

  2. Aquaporin 4 promotes Drug Tolerance to AMG 510 in KRASG12C mutant Non-Small Cell Lung Cancer

    … there has been a recent development of KRASG12C inhibitors that directly target mutant KRAS, thereby arresting its proliferative effects. A recently FDA-approved KRASG12C inhibitor for the treatment of non-small cell lung cancer, Sotorasib (AMG 510), has been shown to produce …

    ucf Repository record for Aquaporin 4 promotes Drug Tolerance to AMG 510 in KRASG12C mutant Non-Small Cell Lung Cancer (opens in a new tab)

  3. Refinement of 3D lung cancer models for automation and patient stratification with mode-of-action studies

    … from glycine to cysteine in codon 12 (KRASG12C). Being considered “undruggable” in previous decades, KRASG12C-inhibitors now paved the way into the standard-of-care for lung adenocarcinoma treatment in the clinics. Still, the overall response rates as well as overall survival of …

    wurz-thes Repository record for Refinement of 3D lung cancer models for automation and patient stratification with mode-of-action studies (opens in a new tab)

  4. Pre-clinical rationale for new indications and novel combinations of the tyrosine kinase inhibitor neratinib in cancer

    … (multi-kinase), crizotinib (ALK) and sotorasib (KRASG12C) was investigated in vitro in HER-driven gastroesophageal, lung, pancreatic and head and neck cancer cell lines by proliferation, apoptosis, migration assays and signalling analysis. Neratinib-sotorasib was further evaluated in 3D spheroids …

    dcu Download PDF for Pre-clinical rationale for new indications and novel combinations of the tyrosine kinase inhibitor neratinib in cancer (opens in a new tab) Embargoed until 2029-02-05

  5. Σηματοδοτικό μονοπάτι του kras στον ΜΜΚΠ: Θεωρητική προσέγγιση και θεραπευτικές στρατηγικές

    … του Kras, και πιο συγκεκριμένα της μετάλλαξης KrasG12C, σοτορασίμπης και ανταγκρασίμπης. Ο ρόλος του Kras στη κυτταρική σηματοδότηση είναι κομβικός για το τελικό αποτέλεσμα που είναι η επιβίωση, ο πολλαπλασιασμός, η απόπτωση, η μετανάστευση του κυττάρου όταν το σήμα φτάσει στον πυρήνα. Η …

    athens Repository record for Σηματοδοτικό μονοπάτι του kras στον ΜΜΚΠ: Θεωρητική προσέγγιση και θεραπευτικές στρατηγικές (opens in a new tab)

  6. Dissecting KRAS Functional Heterogeneity in Patient-Derived Lung Adenocarcinoma Models

    … XDOs and evaluated the novel class of GDP-KRASG12C inhibitors in both XDO and PDX models, studied its short-term pharmacodynamic effects on tumor gene expression and protein signaling, and identified mechanisms of intrinsic resistance to these compound as well as methods of overcoming this …

    toronto-retro Repository record for Dissecting KRAS Functional Heterogeneity in Patient-Derived Lung Adenocarcinoma Models (opens in a new tab)

  7. Modulation of important non-coding RNAs and proteins in cancer with role in transcription and translation initiation regulation

    … their deregulation. To decipher the effects of KRASG12C on transcription and translation initiation in lung adenocarcinoma, generation of TetON-inducible KRASG12C stable A549 and CL1-5 cell lines using TALENs was performed. Further examination of the two cell lines revealed that in CL1-5 cells, …

    greece Repository record for Modulation of important non-coding RNAs and proteins in cancer with role in transcription and translation initiation regulation (opens in a new tab)

  8. Functional contribution of epithelial to mesenchymal transition program on KRASG12D targeting efficacy in pancreatic cancer

    … known for their low efficacy. The emergence of KRASG12C inhibitors, Adagrasib and Sotorasib, paved the way for the development of MRTX1133, a KRASG12D inhibitor. Although MRTX1133 improved survival outcomes in pre-clinical resistance to KRASG12D inhibition develops after prolonged treatment. As …

    uthsc Repository record for Functional contribution of epithelial to mesenchymal transition program on KRASG12D targeting efficacy in pancreatic cancer (opens in a new tab)

  9. An in vivo inflammatory loop potentiates KRAS blockade

    … carboxylmethyltransferase), and AA12 (targeting KRASG12C), and silenced/overexpressed mutant KRAS using custom vectors. We show that KRAS-mutant tumor cells exclusively respond to KRAS blockade in vivo, because the oncogene co-opts host myeloid cells via a C-C-motif chemokine ligand …

    lmu-germany Repository record for An in vivo inflammatory loop potentiates KRAS blockade (opens in a new tab)

  10. Therapeutic Targeting of Protocadherin 7 in Lung Adenocarcinoma

    … tyrosine kinase inhibitor Osimertinib, and the KRASG12C inhibitor Adagrasib. Moreover, a humanized mAb7 decreased tumor growth in an Fc-dependent manner and enhanced antibody dependent cell-mediated cytotoxicity and granzyme B production. These findings provide an important step towards the …

    utswmed Repository record for Therapeutic Targeting of Protocadherin 7 in Lung Adenocarcinoma (opens in a new tab) Embargoed until 2028-12-01

  11. Targeting drug resistant lung adenocarcinoma through hyperactivation of oncogenic pathways

    … a model of trametinib resistance, I found that KRASG12C amplification resulted in a “drug addicted” phenotype, whereby trametinib removal caused ERK hyperactivation lethal to cells. In models of osimertinib resistance, I profiled the potential of multiple genes to induce ERK hyperactivation. I …

    ubc Repository record for Targeting drug resistant lung adenocarcinoma through hyperactivation of oncogenic pathways (opens in a new tab) Download PDF for Targeting drug resistant lung adenocarcinoma through hyperactivation of oncogenic pathways (opens in a new tab)

  12. Mutant Kras Alters Extracellular Vesicle Microrna Sorting In Pancreatic Cystic Neoplasms

    … KRAS, remains largely undruggable, except for KRASG12C mutations, which may be inhibited by sotorasib. Activating mutations in the oncogene KRAS are believed to be the earliest genetic mutation in the development of this disease, occurring in up to 95% of PDACs and 60% of mucinous cysts. While …

    uthsc Repository record for Mutant Kras Alters Extracellular Vesicle Microrna Sorting In Pancreatic Cystic Neoplasms (opens in a new tab)

  13. Synthesis and selection of novel phosphoester oligomers to inhibit the interaction between KRASG12D and RAF1

    … leading to tumour formation. Currently, only KRASG12C has clinically approved small molecule inhibitors, which covalently modify the cysteine at position 12, but there is no way to directly inhibit other more prevalent mutations (for example KRASG12D), and a new approach is needed to target …

    kent Download PDF for Synthesis and selection of novel phosphoester oligomers to inhibit the interaction between KRASG12D and RAF1 (opens in a new tab)

  14. Aktuelle patientenindividuelle Behandlungsansätze beim metastasierten nicht-kleinzelligen Lungenkarzinom

    … langanhaltender Therapieeffekt bei Patienten mit KRASG12C/TP53-Komutationen kontrastiert mit teils erheblich reduziertem Überleben im Falle anderer molekularer Konstellationen. Eine prognostische Einschätzung scheint somit durch ein fokussiertes Genpanel möglich zu sein, welches bereits jetzt im …

    fu-berlin Repository record for Aktuelle patientenindividuelle Behandlungsansätze beim metastasierten nicht-kleinzelligen Lungenkarzinom (opens in a new tab)

  15. Internalising radioimmunoconjugates to target KRas cancer cells for simultaneous radio-ligand therapy and radiosensitisation

    … resistance rapidly emerged. Additionally, KRasG12C mutations are rare in PDAC, with less than 5% of the reported cases showing this mutation. Therefore, despite promising candidates being reported, the development of new and innovative targeted therapies is still urgently needed.</p> …

    oxford Repository record for Internalising radioimmunoconjugates to target KRas cancer cells for simultaneous radio-ligand therapy and radiosensitisation (opens in a new tab)

  16. The Role of METTL21A in Kras-driven Cancers

    … sensitivity of METTL21A depletion cells to the KrasG12C inhibitor, AMG510, treatment. The results suggest that METTL21A-depleted cells were more sensitive to AMG510. Interestingly, there is a synergistic effect between Pifithrin-μ and AMG510 for METTL21A depletion cells. Together, these results …

    uthsc Repository record for The Role of METTL21A in Kras-driven Cancers (opens in a new tab)

  17. Ανάλυση τεκμηρίων στον ορθοκολικό καρκίνο και αντίκτυπος στην κλινική πράξη

    … Study 4: the use of targeted therapy against the KRASG12C mutation in metastatic colon and rectal cancer appears promising. However, there was heterogeneity between the studies analyzed.

    greece Repository record for Ανάλυση τεκμηρίων στον ορθοκολικό καρκίνο και αντίκτυπος στην κλινική πράξη (opens in a new tab)

  18. Overcoming Microenvironmentally Mediated Resistance in Targetable Non-Small Cell Lung Cancer

    The introduction of targeted therapies has resulted in immense success in treating lung cancer patients, where many patients experience long-term remission. Yet, the tumors relapse into an advanced state of disease, and ultimately, treatment failure. This can be ascribed to incomplete eradication …

    usf Repository record for Overcoming Microenvironmentally Mediated Resistance in Targetable Non-Small Cell Lung Cancer (opens in a new tab)